Source: http://www.google.fr/patents/US7364724
Timestamp: 2013-05-21 08:39:33
Document Index: 203027588

Matched Legal Cases: ['Application No. 2003248419', 'Application No. 2003248419', 'Application No. 2003248419', 'Application No. 02702211', 'Application No. 279', 'Application No. 200601204', 'Application No. 92', 'Application No. 92']

Brevet US7364724 - Recombinant super-compound interferon - Google�BrevetsRecherche Images Maps Play YouTube Actualit�s Gmail Drive Plus » Recherche avanc�e dans les brevets | Historique Web | Connexion Recherche avanc�e dans les brevets BrevetsThis invention provides a recombinant super-compound interferon or an equivalent thereof with changed spatial configuration. The super-compound interferon possesses anti-viral or anti-tumor activity and therefore is useful to prevent and treat viral diseases and cancers. This invention also provides...http://www.google.fr/patents/US7364724?utm_source=gb-gplus-shareBrevet US7364724 - Recombinant super-compound interferon Num�ro de publicationUS7364724 B2Type de publicationOctroi Num�ro de demande10/650,365 Date de publication29 avr. 2008 Date de d�p�t28 ao�t 2003 Date de priorit�28 f�vr. 2001Autre r�f�rence de publicationCN1245215CCN1311035AEP1371373A1EP1371373A4EP1371373B1US8114395US20040202641US20080305080US20110189128WO2002080958A1 InventeursRongbing GuoGuangwen WeiRenhuai Zhang Cessionnaire d'origineSichuan Biotechnology Research Center Classification aux �tats-Unis424/85.7435/71.1536/23.52435/252.3435/69.52 Classification internationaleA61P35/02C12N15/19C07H21/04A61P31/20C12N15/20A61P31/22A61K38/00A61P1/16A61P31/16A61P31/18C07K14/555A61P31/12C12P21/04A61P35/00A61P31/00A61P1/00C12N15/09C07K14/435C12N1/20C07H21/00A61K38/21A61P31/14 Classification coop�rativeC07K14/555 Classification europ�enneC07K 14/555R�f�rencesCitations de brevets (22)Citations hors brevets (47) R�f�renc� par (4)Liens externesUSPTO Cession USPTO EspacenetRecombinant super-compound interferonUS 7364724 B2 R�sum� This invention provides a recombinant super-compound interferon or an equivalent thereof with changed spatial configuration. The super-compound interferon possesses anti-viral or anti-tumor activity and therefore is useful to prevent and treat viral diseases and cancers. This invention also provides an artificial gene which codes for the super-compound interferon or its equivalent. Finally, this invention provides methods to produce recombinant super-compound interferon or its equivalent and various uses of said interferon.
Citations de brevets Brevet cit� Date de d�p�t Date de publication D�posant TitreUS46721083 juil. 19859 juin 1987Hoffmann-La Roche Inc.Crystalline human leukocyte interferonUS468193010 ao�t 198421 juil. 1987Hoffmann-La Roche Inc.Immune interferon and a method for its extraction and purificationUS469562312 d�c. 198322 sept. 1987AmgenConsensus human leukocyte interferonUS489747121 sept. 198730 janv. 1990AmgenConsensus human leukocyte interferonUS560223214 d�c. 199411 f�vr. 1997Schering CorporationMethod for producing metal-interferon-α crystalsUS587430418 janv. 199623 f�vr. 1999University Of Florida Research Foundation, Inc.Humanized green fluorescent protein genes and methodsUS597233122 d�c. 199526 oct. 1999Schering CorporationCrystalline interferon alpha for pulmonary delivery and method for producing the sameUS608747823 janv. 199811 juil. 2000The Rockefeller UniversityCrystal of the N-terminal domain of a STAT protein and methods of use thereofUS61141452 d�c. 19985 sept. 2000Human Genome Sciences, Inc.Synferon, a synthetic interferonUS653243723 oct. 199611 mars 2003Cornell Research Foundation, Inc.Crystalline frap complexUS654607427 mars 20018 avr. 2003Astex Technology LimitedProtein crystal structure and method for identifying protein modulatorsUS657969511 oct. 199617 juin 2003President And Fellows Of Harvard CollegePhosphopantetheinyl transferases and uses thereofAU2003248419A1 Titre non disponibleCN1375502A25 oct. 200123 oct. 2002南京药科大学Polyglycol modified recombinant human interferonCN1478545A18 juil. 20033 mars 2004中国科学院微生物研究所Use of compound interferon in the treating of SARS diseaseEP0083734B13 d�c. 19825 mars 1986F. HOFFMANN-LA ROCHE &amp; CO. AktiengesellschaftCrystalline human leukocyte interferonEP0422697A114 d�c. 199017 avr. 1991Amgen Inc.A consensus leukocyte interferon and a gene encoding itEP0736303B130 mars 199625 ao�t 1999F. Hoffmann-La Roche AgInterferon solutionEP0777495B110 oct. 199519 juil. 2000Schering CorporationStable, aqueous alfa interferon solution formulationsWO2005021777A226 ao�t 200410 mars 2005Huiyangtech (Usa), Inc.Uses of spatial configuration to modulate protein functionWO2005034853A226 ao�t 200421 avr. 2005Huiyangtech (Usa), Inc.Uses of interferons with altered spatial structureWO2006134497A29 mars 200621 d�c. 2006Wei, GuangwenUses of recombinant super-compound interferonsCitations hors brevetsR�f�rence1Advisory Action Before the Filing of and Appeal Brief for Guangwen WEI, U.S. Appl. No. 10/928,474, Filed Aug. 26, 2004, Dated May 22, 2007.2Apeler H, et al. "Expression of natural and synthetic genes encoding herpes simplex virus 1 protease in Escherichia coli and purification of the protein", European Journal Of Biochemistry / Febs. Aug. 1, 1997, vol. 247, No. 3, Aug. 1 1997, pp. 890-895, XP002318941, ISSN: 0014-2956.3Australian Examiner's Report for Sichuan Biotechnology Research Center, Australian Application No. 2003248419, Filed Sep. 26, 2003, Dated Dec. 12, 2005.4Australian Examiner's Report for Sichuan Biotechnology Research Center, Australian Application No. 2003248419, Filed Sep. 26, 2003, Dated Jun. 1, 2006.5Australian Notice of Acceptance for Sichuan Biotechnology Research Center, Australian Application No. 2003248419, Filed Sep. 26, 2003, Dated Dec. 18, 2006.6Ausubel et al., Eds., 1999, Chapter Ten, "Analysis of Proteins," form Short Protocols in Molecular Biology, 4th ed., pp. 10-1 to 10-8.7Cinatl et al., 2003, "Treatment of SARS with Human Interferons," The Lancet, 362:293-294.8Day et al. Engineered Disulfide Bond Greatly Increases Specific Activity of RecombinNT Murine Interferon-beta (1992), J. of Interferon Res. 12, pp. 139-143.9Day et al., 1992, "Engineered disulfide bond greatly increases specific activity of recombinant murine interferon-beta," Journal of Interferon Res., 12: 139-143.10Duan et al., 2003, "Anti-SARS virus activities of different recombinant human interferons in cell culture system," Chinese J. Clin. Virol., 17(3):205-208.11EPO Supplementary European Search Report, Application No. EP 02702211, Filed Feb. 28, 2002, Date of completion of the search: Feb. 23, 2005.12European Communication for Sichuan Biotechnology Research Center, European Application No. 02702211.D, Filed Sep. 25, 2003, Dated Dec. 14, 2006.13Guzman Luz-Maria, et al. "Tight regulation, modulation, and high-level expression by vectors containing the arabinose P-BAD promoter", Journal of Bacteriology, vol. 177, No. 14, 1995, pp. 4121-4130, XP002121022, ISSN: 0021-9193.14Higgins et al., 1983, "Intranasal Interferon as Protection Against Experimental Respiratory Coronavirus Infection in Volunteers," Antimicrobial Agents and Chemotherapy, 24(5):713-715.15Holland, C.C. and T.L. Wright, 1994, "New approaches to treatment of chronic viral hepatitis," Pathology (Phila.), 3(1).16Huang Wanzhi, et al. "Use of the arabinose pbad promoter for tightly regulated display of proteins on bacteriophage", Gene (Amsterdam), vol. 251, No. 2, Jun. 27, 2000, pp. 187-197, XP004206676, ISSN: 0378-1119.17Indian Examination Report for Sichuan Biotechnology Research Center, Indian Application No. 279/MUM/2004, Filed Mar. 5, 2004, Dated Aug. 2, 2007.18International Preliminary Examination Report, Application No. PCT/CN02/00128 for Sichuan Biotechnology Research Center, "Recombination Super Compound Interferon Used as Helatitis B Surface Antigen and E Antigen Inhibitor," Filed Feb. 28, 2002, Dated Feb. 15, 2004.19International Publication No. WO 83/04053 for Amgen Inc et al., Published Nov. 24, 1983. PCT/US83/00605 "The Manufacture and Expression of Large Structural Genes".20International Publication No. WO 93/21229 for Amgen Inc et al., Published Oct. 28, 1993. PCT/US93/04471 "Methods and Compositions for the Treatment of Diseases with Interferon While Reducing Side Effects".21International Publication No. WO/02/80958 for Guangwen Wei, Published Oct. 17, 2002. PCT/CN02/00128 "Recombination Super Compound Interferon Used as Hepatitis B Surface Antigen and E Antigen Inhibitor".22International Search Report for International Application No. PCT/US04/28068, filed Aug. 26, 2004 for Huiyangtech (USA) Inc., dated Mar. 4, 2005.23International Search Report, Application No. PCT/CN02/00128 for Sichuan Biotechnology Research Center, "Recombination Super Compound interferon Used as Hepatitis B Surface Antigen and E Antigen Inhibito," Filed Feb. 28, 2002, Dated Aug. 8, 2002, Date of Completion of the Search: Jul. 23, 2002.24International Search Report, Application No. PCT/US2004/028067 for Huiyangtech, Inc., "Uses of interferons with altered spatial structure,"Filed Aug. 26, 2004, Dated Feb. 27, 2006, Date of Completion of the Search: Nov. 2, 2005.25Ivan Amato, Jan. 22, 2007, "Silent No Longer: Researchers Unearth Another Stratum of Meaning in the Genetic Code," Chemical and Engineering News, 85(4):38-40.26Malaysian Examiner's Report for Sichuan Biotechnology Research Center, Malaysian Application No. PI 20033246, Filed Aug. 28, 2003, Dated Mar. 8, 2007.27Nackley, A.G. et al., Dec. 22, 2006, "Human Catechol-O-Methyltransferase Haplotypes Modulate Protein Expression by Altering mRNA Secondary Structure," Science, 314:1930-1932.28Nasoff et al., 1999, "High-level expression of human genes in E. coli," Expression, 6(2): 10-11.29Nasoff, M. High-Level Expression of Human Genes in E. coli. (1999), Expression vol. 6, No. 2, pp. 10-11.30Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority (International Search Report and Written Opinion included), Application No. PCT/IB2006/002340, Filed Mar. 9, 2006, Dated May 10, 2007.31PCT Notification of Transmittal of International Preliminary Report on Patentability for Huiyangtech (USA) Inc., Int'l Application No. PCT/US04/28068, Filed Aug. 26, 2004, Dated May 13, 2005.32Pyrc, K, et al., 2007, "Antiviral strategies against human coronaviruses," Infectious Disorders - Drug Targets, 7:59-66.33Singapore Written Opinion for Huiyangtech (USA), Inc., Singapore Application No. 200601204-1, Filed Feb. 23, 2006, Dated Jul. 19, 2007.34Taiwanese Formal Rejection for Sichuan Biotechnology Research Center, Taiwanese Application No. 92,123,846, Filed Aug. 28, 2003, Dated Dec. 29, 2006.35Taiwanese Office Action for Sichuan Biotechnology Research Center, Taiwanese Application No. 92,123,846, Filed Aug. 28, 2003, Dated Sep. 21, 2006.36U.S. Office Action for Guangwen WEI, U.S. Appl. No. 10/927,975, Filed Aug. 26, 2004, Dated Apr. 3, 2007.37U.S. Office Action for Guangwen WEI, U.S. Appl. No. 10/927,975, Filed Aug. 26, 2004, Dated Sep. 19, 2007.38U.S. Office Action for Guangwen WEI, U.S. Appl. No. 10/928,474, Filed Aug. 26, 2004, Dated Aug. 22, 2006.39U.S. Office Action for Guangwen WEI, U.S. Appl. No. 10/928,474, Filed Aug. 26, 2004, Dated Aug. 9, 2007.40U.S. Office Action for Guangwen WEI, U.S. Appl. No. 10/928,474, Filed Aug. 26, 2004, Dated Feb. 9, 2007.41U.S. Office Action for Guangwen WEI, U.S. Appl. No. 10/928,956, Filed Aug. 26, 2004, Dated Dec. 15, 2006.42U.S. Office Action for Guangwen WEI, U.S. Appl. No. 10/928.956, Filed Aug. 26, 2004, Dated Jun. 14, 2007.43U.S. Office Action for Guangwen WEI, U.S. Appl. No. 11/077,813, Filed Mar. 10, 2005, Dated Aug. 1, 2007.44U.S. Office Action for Guangwen WEI, U.S. Appl. No. 11/077,813, Filed Mar. 10, 2005, Dated Aug. 8, 2006.45U.S. Office Action for Guangwen WEI, U.S. Appl. No. 11/077,813, Filed Mar. 10, 2005, Dated Nov. 27, 2006.46Written Opinion of the International Searching Authority for International Application No. PCT/US04/28068, filed Aug. 26, 2004 for Huiyangtech (USA) Inc., dated Mar. 4, 2004.47Zhao, Z. et al., 2003, "Description and Clinical treatment of an early outbreak of severe Acute Respiratory Syndrome (SARS) in Guangzhou, PR China," Journal of Med. Microbiol., 52:715-720. R�f�renc� par Brevet citant Date de d�p�t Date de publication D�posant TitreUS758564726 ao�t 20048 sept. 2009Wei GuangwenNucleic acid encoding recombinant interferonUS811439518 avr. 200814 f�vr. 2012Sichuan Biotechnology Research CenterTreatment of viral diseases with recombinant interferon αUS82878524 sept. 200916 oct. 2012Superlab Far East LimitedTreatment of viral diseases with recombinant interferon αWO2011072487A116 d�c. 201023 juin 2011Sichuan Huiyang Life Science & Technology Corp.Crystal of recombinant interferon with altered spatial configuration, three-dimensional structure and uses thereofFaire pivoterImage d'origineAccueil Google - Plan du site - T�l�chargements par lot sur l'USPTO - R�gles de confidentialit� - Conditions d'utilisation - � propos de Google�Brevets - Envoyer des commentairesDonn�es fournies par IFI CLAIMS Patent Services©2012 Google